Page 4 - Anjali Singh

Beyond GLP-1, Novo eyes next-gen obesity drugs: Vikrant Shrotriya

Novo Nordisk plans to defend its obesity drug leadership in India as semaglutide patent expiry fuels competition from nearly 50 new market entrants

Uzbekistan eyes Indian pharma firms to achieve $10 bn output by 2035

The Central Asian nation is offering tax breaks, infrastructure support and regulatory incentives as it seeks to become a pharmaceutical manufacturing hub for the CIS region

PM Modi meets Citigroup Chair Jane Fraser, discusses investment plans

The Prime Minister and Citi Chair Jane Fraser discussed investment opportunities, capital flows, artificial intelligence and alternative energy as part of India's long-term growth agenda

Auto component sector margins to moderate amid West Asia conflict: Crisil

Operating margins of auto component makers are expected to decline by up to 150 basis points this fiscal year as higher raw material and freight costs weigh on profitability, according to Crisil

Indian tyre exports hit record high in FY26 despite global challenges

Exports rose 9 per cent to ₹27,312 crore in FY26 as tyre makers expanded into new markets and strengthened manufacturing capacity despite trade and logistics challenges

Alkem launches semaglutide pre-filled syringes in India at ₹350

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

Two-wheeler makers post strong May sales on resilient domestic demand

Inventory replenishment, resilient demand for premium models and stronger exports helped India's leading two-wheeler manufacturers record healthy growth in May

Organised aesthetic clinics set to gain from tighter rules on Botox

CDSCO's move can lead to the formalisation of more than 35,000 skin clinics, stop the mushrooming of single-operator setups run by unqualified practitioners

Alkem Q4 profit falls 23% on one-off hit; sees strong FY27 pipeline

The drugmaker said strong domestic branded generics and international business growth helped drive record EBITDA performance in FY26

Sanofi unveils AI-powered platform for early rare disease detection

Sanofi's AI-powered AccelRare platform aims to help doctors identify rare diseases faster and improve referrals to specialist treatment centres in India

Sun Pharma's Unloxcyt posts 50% response rate in skin cancer study

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

JK Tyre Q4FY26 profit nearly doubles; plans ₹4,980 crore expansion

The tyre maker posted strong fourth-quarter earnings driven by robust demand and announced a phased capacity expansion amid rising domestic and export opportunities

Tyre, auto-component firms hint at fresh price hikes amid input cost rise

Tyre and auto-component makers raise prices as raw material and energy inflation erodes margins

High-value clinical research marks gradual shift to India: Parexel

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Sun Pharma's US generics business remains under pressure in FY26

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

Eris Lifesciences Q4 profit jumps three-fold to ₹281.6 cr; shares surge 11%

The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent

ICRA projects 3-5% growth in domestic two-wheeler volumes for FY27

Credit rating agency says domestic two-wheeler wholesale volumes may grow 3-5% in FY27, while exports and electric vehicle demand continue to support the industry

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

Nephrocare Health Services profit up 75% in FY26 on strong dialysis demand

NephroPlus posted a 74.6% jump in FY26 profit as higher dialysis volumes and rapid international expansion boosted revenue and margins